Dioseve获得14.5亿日元资金，以推进基于iPS细胞的体外受精（IVF）支持技术，并聘请《时代》百大科学家担任顾问-动脉网

Dioseve Secures JPY 1.45 Billion to Advance iPS Cell‑Based IVF Support, Adds TIME100 Scientist as Advisor

CISION 等信源发布 2026-06-17 00:00



可切换为仅中文







Funding round and NEDO Deep Tech Startup Support Program selection will support development and clinical adoption of DIOS

融资轮次及入选NEDO深科技初创企业支持计划将助力DIOS的开发与临床应用推广

‑

101, an iPS cell

101，一种诱导多能干细胞

‑

derived co

衍生公司

‑

culture designed to reduce the burden of IVF treatment.

旨在减轻试管婴儿治疗负担的培养体系。

TOKYO

东京

，

June 16, 2026

2026年6月16日

/PRNewswire/ -- Dioseve Inc. ('Dioseve'), a Tokyo-based fertility biotech company developing iPS cell-derived ovarian support technologies for in vitro oocyte maturation to reduce the physical and emotional burden of IVF, today announced the completion of an extended Series A round totaling over JPY 1.0 billion (around USD 7 million) via a third-party allotment of new .

/美通社/ -- 总部位于东京的生育生物技术公司Dioseve Inc.（“Dioseve”）致力于开发基于诱导多能干细胞（iPS细胞）的卵巢支持技术，用于体外卵母细胞成熟，以减轻试管婴儿（IVF）治疗带来的身心负担。该公司今日宣布，通过第三方配售新股，完成扩展后的A轮融资，总额超过10亿日元（约合700万美元）。

shares. The financing

股份。融资

brings the company's cumulative equity funding to JPY 2.5 billion.

使公司累计股权融资额达到25亿日元。

Archetype Ventures served as lead investor, with continued participation from DG Daiwa Ventures and Mirai Door (Asuka Innovation Fund). New investors D4V, Shionogi & Co., Ltd., and Pangaea Ventures also joined the round.

Archetype Ventures 领投，DG Daiwa Ventures 和 Mirai Door（Asuka Innovation Fund）继续跟投。新投资者 D4V、盐野义制药株式会社和 Pangaea Ventures 也参与了本轮融资。

In addition, Dioseve has been selected for the 8th cohort of the NEDO Deep Tech Startup Support Program (DTSU), a Japanese government‑backed initiative that supports early-stage companies developing high‑risk, high‑impact technologies. When combined with this non-dilutive support, the company's total funding to date reaches JPY 2.9 billion (around USD 20 million)..

此外，Dioseve 入选了日本新能源产业技术综合开发机构（NEDO）深科技初创企业支持计划（DTSU）第八期项目。该计划由日本政府支持，旨在扶持开发高风险、高影响力技术的早期企业。加上这笔非稀释性资金支持，该公司迄今累计融资总额达 29 亿日元（约合 2,000 万美元）。

NEDO is Japan's primary public research and development funding agency under METI, Ministry of Economy, Trade and Industry of Japan.

NEDO是日本经济产业省（METI）下属的主要公共研发资助机构。

The funds raised in this round will be used primarily to advance the development and clinical translation of ReproNest, building out manufacturing and quality management infrastructure, and expanding regulatory and business development activities.

本轮募集的资金将主要用于推进ReproNest的研发和临床转化，建设生产和质量管理基础设施，并扩大监管和业务拓展活动。

'IVF remains physically, emotionally, and financially demanding for many patients,' said Kazuma Kishida, CEO of Dioseve. 'With this new funding and support from NEDO, we plan to accelerate the development of our iPS cell‑derived co‑culture technology, with the goal of making IVF treatment less burdensome and more accessible in everyday clinical practice.'.

“对许多患者而言，试管婴儿（IVF）在身体、情感和经济方面仍然负担沉重。”Dioseve首席执行官岸田一马表示，“借助这笔新资金以及日本新能源与产业技术综合开发机构（NEDO）的支持，我们计划加速开发源自诱导多能干细胞（iPS细胞）的共培养技术，旨在减轻试管婴儿治疗的负担，使其在日常临床实践中更易于普及。”

About ReproNest

关于 ReproNest

Dioseve is a reproductive medicine company focused on the development of ReproNest, a co-culture product candidate that uses iPS cell-derived ovarian support cell-like cells to support oocyte maturation ex vivo. Unlike cell therapies, ReproNest is designed for use within the IVF process and is not administered directly to patients..

Dioseve 是一家生殖医学公司，专注于开发 ReproNest，这是一种共培养候选产品，利用诱导多能干细胞（iPS 细胞）衍生的卵巢支持细胞样细胞，在体外支持卵母细胞成熟。与细胞疗法不同，ReproNest 专为在体外受精（IVF）过程中使用而设计，并不直接施用于患者。

Conventional IVF protocols typically require around 10 days of hormonal stimulation, repeated clinic visits, self-administered injections, and substantial medication costs, all of which place significant physical and emotional demands on patients. ReproNest is intended to address these challenges by enabling minimal stimulation approaches combined with in vitro oocyte maturation (IVM), reducing the overall treatment burden..

传统体外受精（IVF）方案通常需要约10天的激素刺激、多次诊所就诊、自我注射以及高昂的药物费用，所有这些都给患者带来了巨大的身心压力。ReproNest旨在通过结合最小刺激方案与体外卵母细胞成熟（IVM）技术来应对这些挑战，从而降低整体治疗负担。

Preclinical data to date suggest that ReproNest may improve oocyte maturation under experimental conditions compared with standard IVM culture systems. Dioseve is currently focused on validating its manufacturing processes, quality standards, and reproducibility ahead of clinical translation.

迄今为止的临床前数据表明，与标准体外成熟（IVM）培养系统相比，ReproNest 可能在实验条件下改善卵母细胞的成熟。Dioseve 目前正专注于在临床转化之前验证其生产工艺、质量标准和可重复性。

Looking ahead, the company sees additional applications in fertility preservation, including oocyte cryopreservation and pre-treatment fertility preservation for oncology patients. Ultimately, the company aims to contribute to extending women's reproductive options by making in vitro oocyte maturation a more practical part of routine care..

展望未来，该公司看到了在生育力保存领域的更多应用，包括卵母细胞冷冻保存以及肿瘤患者的治疗前生育力保存。最终，该公司旨在通过使体外卵母细胞成熟成为常规护理中更为实用的一部分，为扩展女性的生殖选择做出贡献。

Professor Katsuhiko Hayashi Joins as Scientific Advisor

林克彦教授出任科学顾问

Professor Katsuhiko Hayashi of the Osaka University Graduate School of Medicine has joined Dioseve as Scientific Advisor.

大阪大学医学研究科的林克彦教授已加入Dioseve，担任科学顾问。

A globally recognized pioneer in reproductive biology, Professor Hayashi has published numerous landmark findings in germ cell research using iPS cells. He was named to Nature's 'Nature's 10' in 2023 and TIME magazine's 'TIME100' in 2024. His involvement is expected to deepen Dioseve's scientific foundation and accelerate progress toward new treatment options in assisted reproductive medicine..

作为生殖生物学领域全球公认的先驱，林教授利用诱导多能干细胞（iPS细胞）在生殖细胞研究方面发表了多项里程碑式的成果。他入选了《自然》杂志2023年度“自然十大人物”以及《时代》周刊2024年度“时代百大人物”。他的加入有望夯实Dioseve的科学基础，并加速辅助生殖医学新治疗方案的研发进程。

About Dioseve Inc.

关于 Dioseve 公司

Dioseve Inc. is a Tokyo-based fertility biotech startup developing iPS cell-derived co-culture technologies aimed at improving outcomes in assisted reproduction. The company's lead program, ReproNest, aims to improve in vitro oocyte maturation and reduce the burden associated with conventional IVF treatment..

Dioseve Inc. 是一家总部位于东京的生育生物技术初创公司，致力于开发源自诱导多能干细胞（iPS细胞）的共培养技术，旨在改善辅助生殖的治疗结果。公司的核心项目 ReproNest 旨在提高卵母细胞体外成熟率，并减轻与传统试管婴儿（IVF）治疗相关的负担。

Headquarters:

总部：

Shin-Kiba, Koto-ku, Tokyo, Japan

日本东京都江东区新木场

CEO:

首席执行官：

Kazuma Kishida

岸田一真

Business Areas:

业务领域：

Research, development, and manufacturing of assisted reproductive medicine products utilizing iPS cell differentiation technology